Literature DB >> 15882803

UCHL1 is associated with Parkinson's disease: a case-unaffected sibling and case-unrelated control study.

Maurizio Facheris1, Kari J Strain, Timothy G Lesnick, Mariza de Andrade, James H Bower, J Eric Ahlskog, Julie M Cunningham, Sarah Lincoln, Mathew J Farrer, Walter A Rocca, Demetrius M Maraganore.   

Abstract

To avoid the possible confounding effect of population stratification, we employed a discordant sibling study design and a liberalization of the sibling transmission disequilibrium test to confirm the association of the S18Y variant of the ubiquitin carboxi-terminal hydrolase L1 (UCHL1) gene with Parkinson's disease (PD). The study included 497 case-control pairs (427 case-unaffected sibling pairs and 70 case-unrelated control pairs). Analyses confirmed a significant inverse association of the UCHL1 S18Y polymorphism with PD overall (OR=0.18, 95% CI=0.05-0.64, p=0.002, recessive model) and in several strata.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15882803     DOI: 10.1016/j.neulet.2005.02.008

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  8 in total

1.  Common variants in PARK loci and related genes and Parkinson's disease.

Authors:  Sun Ju Chung; Sebastian M Armasu; Joanna M Biernacka; Timothy G Lesnick; David N Rider; Sarah J Lincoln; Alexandra I Ortolaza; Matthew J Farrer; Julie M Cunningham; Walter A Rocca; Demetrius M Maraganore
Journal:  Mov Disord       Date:  2010-12-13       Impact factor: 10.338

Review 2.  Association between ubiquitin carboxy-terminal hydrolase-L1 S18Y variant and risk of Parkinson's disease: the impact of ethnicity and onset age.

Authors:  Ying Liu; Yan-Yan Chen; Hui Liu; Ci-Jiang Yao; Xiao-Xia Zhu; Dao-Jun Chen; Jin Yang; You-Jin Lu; Ji-Yu Cao
Journal:  Neurol Sci       Date:  2014-11-06       Impact factor: 3.307

3.  Lack of evidence for an association between UCHL1 S18Y and Parkinson's disease.

Authors:  Carolyn M Hutter; Ali Samii; Stewart A Factor; John G Nutt; Donald S Higgins; Thomas D Bird; Alida Griffith; John W Roberts; Berta C Leis; Jennifer S Montimurro; Denise M Kay; Karen L Edwards; Haydeh Payami; Cyrus P Zabetian
Journal:  Eur J Neurol       Date:  2007-12-18       Impact factor: 6.089

Review 4.  alpha-Synuclein: a therapeutic target for Parkinson's disease?

Authors:  Kathleen A Maguire-Zeiss
Journal:  Pharmacol Res       Date:  2008-09-16       Impact factor: 7.658

5.  A system-based comparison of gene expression reveals alterations in oxidative stress, disruption of ubiquitin-proteasome system and altered cell cycle regulation after exposure to cadmium and methylmercury in mouse embryonic fibroblast.

Authors:  Xiaozhong Yu; Joshua F Robinson; Jaspreet S Sidhu; Sungwoo Hong; Elaine M Faustman
Journal:  Toxicol Sci       Date:  2010-01-08       Impact factor: 4.849

6.  Ubiquitin carboxyl-terminal esterase L1 (UCHL1) S18Y polymorphism in patients with cataracts.

Authors:  Thiemo Rudolph; Annica Sjölander; Mona Seibt Palmér; Lennart Minthon; Anders Wallin; Niels Andreasen; Gunnar Tasa; Erkki Juronen; Kaj Blennow; Henrik Zetterberg; Madeleine Zetterberg
Journal:  Ophthalmic Genet       Date:  2011-01-26       Impact factor: 1.803

Review 7.  Association between the ubiquitin carboxyl-terminal esterase L1 gene (UCHL1) S18Y variant and Parkinson's Disease: a HuGE review and meta-analysis.

Authors:  Margaret Ragland; Carolyn Hutter; Cyrus Zabetian; Karen Edwards
Journal:  Am J Epidemiol       Date:  2009-10-28       Impact factor: 4.897

8.  UCHL1 S18Y variant is a risk factor for Parkinson's disease in Japan.

Authors:  Yoshihiro Miyake; Keiko Tanaka; Wakaba Fukushima; Chikako Kiyohara; Satoshi Sasaki; Yoshio Tsuboi; Tatsuo Yamada; Tomoko Oeda; Hiroyuki Shimada; Nobutoshi Kawamura; Nobutaka Sakae; Hidenao Fukuyama; Yoshio Hirota; Masaki Nagai
Journal:  BMC Neurol       Date:  2012-07-28       Impact factor: 2.474

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.